ABBV Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

219.375

Open

215.900

VWAP

217.97

Vol

5.19M

Mkt Cap

380.57B

Low

215.900

Amount

1.13B

EV/EBITDA(TTM)

14.77

Total Shares

1.77B

444.08B

EV/OCF(TTM)

20.92

P/S(TTM)

6.08

AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.

Events Timeline

(ET)

2026-05-29

08:40:00

New

AbbVie’s Venclyxto Receives Expanded Indication from EU

2026-05-27 (ET)

2026-05-27

18:30:00

AbbVie’s DECNUPAZ Approved by FDA for BPDCN Treatment

2026-05-27

15:30:00

AbbVie Receives FDA Approval for Decnupaz in Adults

2026-05-22 (ET)

2026-05-22

08:10:00

AbbVie’s Maviret Receives Positive Opinion from EU Medicines Agency

2026-05-21 (ET)

2026-05-21

16:20:00

Allergan Aesthetics Receives Positive Opinion from EMA

2026-04-30 (ET)

2026-04-30

16:30:00

Dow Rises 790.33 Points, Nasdaq Gains 219.07 Points

News

8.5

12:41 PMNewsfilter

PinnedVENCLYXTO Receives Expanded EU Indication Approval

8.5

15:03 PMNASDAQ.COM

Regulatory Approvals and Collaborations in Biotech Sector

9.0

14:03 PMNASDAQ.COM

AbbVie Receives EU Approval for Expanded VENCLYXTO Indications

8.5

12:56 PMPRnewswire

European Commission Approves Expanded Indication for VENCLYXTO

8.5

12:56 PMPRnewswire

AbbVie Expands VENCLYXTO Indication for CLL Treatment

8.5

11:06 AMFool

Analysis of High-Yield Dividend ETF Investments

18 Analyst Rating

Wall Street analysts forecast ABBV stock price to rise

12 Buy

6 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

223.00

Averages

252.00

High

289.00

Current: 0.000

Low

223.00

Averages

252.00

High

289.00

Evercore ISI

NULL

Outperform

maintain

$236 -> $235

AI Analysis

2026-05-15

Reason

Evercore ISI

Price Target

$236 -> $235

AI Analysis

2026-05-15

maintain

NULL

Outperform

Reason

Evercore ISI lowered the firm's price target on AbbVie to $235 from $236 and keeps an Outperform rating on the shares.

Piper Sandler

Overweight

maintain

$294 -> $298

2026-05-14

Reason

Piper Sandler

Price Target

$294 -> $298

2026-05-14

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on AbbVie to $298 from $294 and keeps an Overweight rating on the shares. The depth of AbbVie's inflammatory bowel disease pipeline remains the focus of significant investor attention, the firm says. Given the white-hot nature of the IBD drug development landscape, management's advancement of novel combination approaches in IBD is undoubtedly a welcome development. That said, one of the considerations that renders AbbVie shares attractive in Piper's view is the range of R&D shots-on-goal that continue to fall under the broader investor radar.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ABBV

Unlock Now

Valuation Metrics

The current forward P/E ratio for AbbVie Inc (ABBV.N) is 15.11, compared to its 5-year average forward P/E of 13.56. For a more detailed relative valuation and DCF analysis to assess AbbVie Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

13.56

Current PE

15.11

Overvalued PE

16.28

Undervalued PE

10.85

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

12.86

Current EV/EBITDA

14.14

Overvalued EV/EBITDA

15.92

Undervalued EV/EBITDA

9.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.00

Current PS

5.24

Overvalued PS

5.77

Undervalued PS

4.23

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

new IPO to buy

Intellectia · 21 candidates

Market Cap: >= 500.00MRegion: USVolume: >= 500,000Analyst Consensus: Strong Buy, Moderate Buy, HoldRsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $0.00Is Trending: True

Ticker

Name

Market Cap$

LLY

Eli Lilly and Co

1000.00B

LRCX

Lam Research Corp

403.53B

ABBV

AbbVie Inc

376.54B

General Electric Co

328.12B

GLW

Corning Inc

168.83B

General Dynamics Corp

93.20B

stocks up in a down market

Intellectia · 87 candidates

Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Week Price Change Pct: >= $0.00Month Price Change Pct: >= $0.00Is Index Component: GSPCEma 20: >= 0Macd: bullish

Ticker

Name

Market Cap$

AAPL

Apple Inc

4.39T

WMT

Walmart Inc

1.07T

XOM

Exxon Mobil Corp

673.76B

Visa Inc

625.00B

COST

Costco Wholesale Corp

485.50B

CSCO

Cisco Systems Inc

455.74B

which megacap surged max yesterday

Intellectia · 64 candidates

Region: USMarket Cap Category: mega

Ticker

Name

Market Cap$

UNH

UnitedHealth Group Inc

359.98B

Philip Morris International Inc

291.34B

NFLX

Netflix Inc

369.12B

ABBV

AbbVie Inc

367.25B

LLY

Eli Lilly and Co

932.20B

COST

Costco Wholesale Corp

453.36B

what stock earnings next week

Intellectia · 133 candidates

Market Cap: >= 10.00BPrice: >= $10.00Is Index Component: GSPCMonthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

GOOG

Alphabet Inc

4.09T

MSFT

Microsoft Corp

3.09T

AMZN

Amazon.com Inc

2.74T

Whales Holding ABBV

The Glenmede Trust Company, National Association

Mubadala Investment Company PJSC

Rakuten Investment Management, Inc.

Texas Yale Capital Corp.

SteelPeak Wealth, LLC

Amundi Luxembourg S.A.

Trading Trends

People Also Watch

Frequently Asked Questions

What is AbbVie Inc (ABBV) stock price today?

The current price of ABBV is 218.63 USD — it has increased 1.5

What is AbbVie Inc (ABBV)'s business?

What is the price predicton of ABBV Stock?

Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is252.00 USD with a low forecast of 223.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is AbbVie Inc (ABBV)'s revenue for the last quarter?

AbbVie Inc revenue for the last quarter amounts to 15.00B USD, increased 12.43

What is AbbVie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

AbbVie Inc. EPS for the last quarter amounts to 0.39 USD, decreased -45.83

How many employees does AbbVie Inc (ABBV). have?

AbbVie Inc (ABBV) has 57000 emplpoyees as of May 29 2026.

What is AbbVie Inc (ABBV) market cap?

Today ABBV has the market capitalization of 380.57B USD.

ABBV Overview

ABBV Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding ABBV

Trading Trends

People Also Watch

Frequently Asked Questions

What is AbbVie Inc (ABBV) stock price today?

What is AbbVie Inc (ABBV)'s business?

What is the price predicton of ABBV Stock?

What is AbbVie Inc (ABBV)'s revenue for the last quarter?

What is AbbVie Inc (ABBV)'s earnings per share (EPS) for the last quarter?

How many employees does AbbVie Inc (ABBV). have?

What is AbbVie Inc (ABBV) market cap?